April 18, 2025

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Julian Friedrich from the DKFZ, HI-STEM* and Heidelberg University Hospital (UKHD) was included in the renowned Forbes ‘30 Under 30 Europe’ list in the Science & Healthcare category.

The physician and cancer researcher, who has headed the Haematology and Immune Engineering junior research group since this year, initially developed successful approaches to reactivate the immune system against brain tumours.

With his current research, Friedrich aims to develop innovative strategies to reprogramme the human immune system by integrating synthetic immunology, genome editing and AI-controlled bioengineering. The aim is to prevent cancer, strengthen immune resilience and promote healthy ageing.

With this award, the US business magazine Forbes annually recognises outstanding young personalities under the age of 30 who stand out in their fields through their innovative strength, social relevance and exceptional achievements.


*The Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) gGmbH was founded in 2008 as a public-private partnership between the DKFZ and the Dietmar Hopp Foundation.

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp